Non-coding RNA-mediated TGF-β1/Smads Signaling Pathway and Liver Fibrosis， and Intervention by Active Components of Chinese Medicinal： A Review
10.13422/j.cnki.syfjx.20221723
- VernacularTitle:非编码RNA介导TGF-β1/Smads信号通路与肝纤维化及中药活性成分干预研究进展
- Author:
Yong CHEN
1
;
Ruisheng WU
1
;
Jingjing WANG
1
;
Le QIN
1
;
Guidong HUANG
1
;
Zhipin ZHOU
2
Author Information
1. Guangxi University of Chinese Medicine， Nanning 530200， China
2. Liuzhou People's Hospital， Guangxi Zhuang Autonomous Region Health Commission Guangxi Clinical Diseases Biotechnology Research Key Laboratory， Liuzhou Gastrointestinal Proprietary Chinese Medicine Engineering and Technology Research Center， Guangxi Medical University， Liuzhou 545006， China
- Publication Type:Journal Article
- Keywords:
transforming growth factor-β1 （TGF-β1）/Smads signaling pathway;
non-coding RNA;
liver fibrosis;
hepatic stellate cell;
active components of Chinese medicinal
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(7):252-261
- CountryChina
- Language:Chinese
-
Abstract:
Liver fibrosis is a wound healing response that occurs in the setting of chronic liver injury and is caused by imbalance in the synthesis and degradation of extracellular matrix （ECM）. If left untreated， it can progress to liver cirrhosis and hepatocellular carcinoma. The activation of hepatic stellate cell （HSC） is now well established as a central driver of liver fibrosis. The activated HSC will transform into myofibroblasts that produce ECM protein. Transforming growth factor-β1 （TGF-β1） can induce the activation of hepatic stellate cell （HSC）， and TGF-β1/Smads signaling pathway is one of the important pathways to promote liver fibrosis. Non-coding RNA （ncRNA） does not encode proteins during the transcription but plays an important regulatory role in the post-transcriptional process of genes. Accumulating evidence shows that the occurrence of liver fibrosis is closely related to the abnormal expression of ncRNA which participates in the activation of HSC by regulating TGF-β1 signal transduction and then affects the process of liver fibrosis. MiRNA-mediated TGF-β1/Smads signaling pathway can not only promote liver fibrosis but also play a role in anti-fibrosis. Long non-coding RNA （lncRNA） not only promotes the development of liver fibrosis by binding to target genes but also enhances TGF-β1 signal transduction by acting as competitive endogenous RNA. circular RNA （circRNA） acts as a ''sponge'' to regulate TGF-β1/Smads pathway， thereby inhibiting HSC activation and exerting the anti-liver fibrosis effect. Chinese medicinal plays an essential part in the prevention and treatment of liver fibrosis， and the active components can inhibit TGF-β1/Smads pathway by regulating the expression of miRNA， thus alleviating liver fibrosis. This article reviews the role and mechanism of miRNA-， lncRNA- and circRNA-mediated TGF-β1/Smads signaling pathway in liver fibrosis and summarizes the anti-liver fibrosis effect of active components of Chinese medicinals by regulating miRNA-mediated TGF-β1/Smads signaling pathway， which can serve as a reference for clinical treatment of liver fibrosis and the development of new drugs.
